April 20, 2024
Market Now
Crystal Genomics cinches W119.3b deal in Russia
[DISCLOSURE] Crystal Genomics (083790) announced on Nov. 19 that it has signed an exclusive contract worth 119.3 billion won (US$105.72 million) with Russia’s PharmArtis International to supply Acelex, a broad-spectrum antibiotic used to treat osteoarthritis, in Russia, on condition that the Russian partner gains approval from local authorities within 36 months.
The contract is valid for 10 years after launch.
By Hwang You-mee (glamazon@heraldcorp.com)
The contract is valid for 10 years after launch.
By Hwang You-mee (glamazon@heraldcorp.com)
